There are also some other miRNAs reported in the past decade, such as miR-29 (proved to have an anti-tumor effect by targeting TRAF4 which can be affected by BCR inhibitors and selectively delivered to CLL cells [73, 74]), miR-125a-5p/miR-34a-5p (as valuable markers to predict Richter syndrome (RS) development in CLL patients [75]), and miR-150 (much abundant expressed in CLL and attached to disease outcome via GAB1 and FOXP1 [76]). This evidence concerns the gene FOXP1 and B-cell chronic lymphocytic leukemia.